Instil Bio, Inc.
TIL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001789769
No open-market purchases or sales by Instil Bio, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $29.2M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Instil Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Instil Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| McGaughy R Kent Jr | Director | 8,218,467Indirect | Jun 12, 2026 | 1 |
| Gibson Neil W | Director | – | Jun 12, 2026 | 1 |
| Binder Gwendolyn | Director | – | Jun 12, 2026 | 1 |
| Matcham George | Director | – | Jun 12, 2026 | 1 |
| Laumas Sandeep | CFO and CBO | 0 | Sep 12, 2025 | 0 |
| Crouch Bronson | CEO and Chairman | – | Apr 28, 2025 | 0 |
| Nielsen Jack | Director | – | Jan 10, 2024 | 0 |
| Ray Sumita | Chief Legal and Admin Officer | – | Jan 20, 2023 | 0 |
| Moore Timothy L. | Chief Operating Officer | – | Sep 6, 2022 | 0 |
| Chiruvolu Vijay | Chief Technical Officer | – | May 25, 2022 | 0 |
| Roberts Zachary | Chief Medical Officer | – | Mar 7, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 12, 2025 (view filing) | Sep 10 | 2 days | Laumas SandeepCFO and CBO | SSale | −30.0K | $23.39 | −$701.7K | −100.0%0 after | 2 lots |